Barclays upgrades Croda on activist investor, cost cutting plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
BMO on Pfizer (PFE) and Trump Deal: 'Announcement serves as a positive to the BioPharma sector'
September 30, 2025 12:44 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $30.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Pfizer and Trump announcement looks to address push from Trump administration for MFN pricing in the US. President Trump's announcement with Pfizer appears to reduce the cost of products for Medicaid customers and form an agreement that new product launches will be listed at the MFN price. While commentary from the call suggests... More
